American Century Companies Inc. Boosts Stake in Artivion, Inc. $AORT

American Century Companies Inc. lifted its holdings in Artivion, Inc. (NYSE:AORT) by 14.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,406 shares of the company’s stock after buying an additional 8,635 shares during the quarter. American Century Companies Inc. owned 0.16% of Artivion worth $1,632,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of AORT. Legacy Advisors LLC purchased a new stake in shares of Artivion in the first quarter valued at approximately $28,000. MCF Advisors LLC boosted its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Artivion in the fourth quarter valued at approximately $64,000. Raymond James Financial Inc. purchased a new stake in Artivion during the fourth quarter worth $275,000. Finally, Natixis Advisors LLC boosted its position in Artivion by 16.4% during the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company’s stock worth $310,000 after purchasing an additional 1,777 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 10,000 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.37, for a total transaction of $443,700.00. Following the completion of the sale, the senior vice president directly owned 172,129 shares in the company, valued at $7,637,363.73. This represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the sale, the chief executive officer owned 852,783 shares of the company’s stock, valued at $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 115,990 shares of company stock valued at $4,435,823. Insiders own 8.10% of the company’s stock.

Artivion Stock Performance

Artivion stock opened at $43.67 on Wednesday. The firm has a market capitalization of $2.06 billion, a P/E ratio of -103.98 and a beta of 1.70. The stock has a fifty day moving average price of $35.58 and a 200 day moving average price of $29.50. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $45.07. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion’s quarterly revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on AORT. Wall Street Zen upgraded Artivion from a “hold” rating to a “buy” rating in a research report on Monday, August 25th. Stifel Nicolaus boosted their target price on Artivion from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. JMP Securities boosted their target price on Artivion from $33.00 to $42.00 and gave the stock a “market outperform” rating in a research report on Friday, August 8th. Finally, Needham & Company LLC boosted their target price on Artivion from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Artivion currently has a consensus rating of “Buy” and a consensus target price of $40.63.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.